Tiziana Life Sciences signs MOU at Riyadh Global Medical Biotechnology Summit
TLSA•Trial focus and partners
The trial would focus on patients responding poorly to anti-CD20 therapy alone, potentially due to untreated neuroinflammation.
Partners include King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, and the Foundation for Neurologic Diseases.
Program added alongside existing Phase 2 study
The MOU adds a relapsing-remitting MS program while the company keeps its blinded Phase 2 trial in non-active secondary progressive MS.
MOU signed in Riyadh for relapsing-remitting MS trial
Tiziana Life Sciences signed an MOU at the Riyadh Global Medical Biotechnology Summit in Riyadh on September 16, 2026.
The agreement targets a clinical trial combining intranasal foralumab with anti-CD20 therapy in relapsing-remitting multiple sclerosis.
